PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
18.13%
Positive revenue growth while CRON.TO is negative. John Neff might see a notable competitive edge here.
126.49%
Gross profit growth under 50% of CRON.TO's 256.46%. Michael Burry would be concerned about a severe competitive disadvantage.
7.01%
EBIT growth below 50% of CRON.TO's 78.03%. Michael Burry would suspect deeper competitive or cost structure issues.
7.01%
Operating income growth under 50% of CRON.TO's 81.88%. Michael Burry would be concerned about deeper cost or sales issues.
-223.94%
Negative net income growth while CRON.TO stands at 75.57%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-151.50%
Negative EPS growth while CRON.TO is at 75.81%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-151.50%
Negative diluted EPS growth while CRON.TO is at 75.81%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.66%
Share count expansion well above CRON.TO's 0.68%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.66%
Diluted share count expanding well above CRON.TO's 0.21%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-1622.35%
Negative OCF growth while CRON.TO is at 5.64%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-40695.39%
Negative FCF growth while CRON.TO is at 5.10%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
591.73%
5Y revenue/share CAGR under 50% of CRON.TO's 2070.29%. Michael Burry would suspect a significant competitive gap or product weakness.
590.91%
3Y revenue/share CAGR above 1.5x CRON.TO's 201.61%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-9912.68%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-1199.97%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-255.95%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-2334.26%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-938.00%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-207.50%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
9571.99%
10Y equity/share CAGR above 1.5x CRON.TO's 1732.64%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
979.62%
5Y equity/share CAGR is in line with CRON.TO's 1065.81%. Walter Schloss would see parallel mid-term profitability and retention policies.
63.77%
3Y equity/share CAGR above 1.5x CRON.TO's 6.46%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.86%
Our AR growth while CRON.TO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-1.92%
Inventory is declining while CRON.TO stands at 12.96%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-0.65%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-2.43%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-6.92%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
119.27%
We increase R&D while CRON.TO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
34.23%
We expand SG&A while CRON.TO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.